Anavex Life Sciences’ Blarcamesine Demonstrates Promising Results in Alzheimer’s Disease
Anavex has released promising results from a phase 2b/3 clinical trial evaluating
its investigational drug, blarcamesine, for early Alzheimer’s disease. The
study, conducted across multiple centers, revealed significant reductions in
amyloid-ß biomarkers, a critical indicator of Alzheimer’s progression.
The trial enrolled 508 participants, with 338 receiving blarcamesine and 170 on placebo. Over 48
weeks, the drug demonstrated a notable slowing of brain atrophy on MRI scans
and validated its efficacy through primary endpoints like the Alzheimer’s
Disease Assessment Scale-Cognitive (ADAS-Cog) and Alzheimer’s Disease
Cooperative Study-Activities of Daily Living (ADCS-ADL).
In terms of cognitive function, blarcamesine-treated patients exhibited a significant
increase in plasma Aβ42/40 ratio, indicating a strong anti-amyloid effect.
Additionally, MRI findings showed a significant reduction in brain volume loss,
especially in the whole brain, when compared to the placebo group.
Dr. Marwan Noel Sabbagh, chairman of the Scientific Advisory Board, remarked, “The advantage of
blarcamesine is that it is a small oral molecule offering clinical benefits on
cognition and neurodegeneration. Its route of administration and safety profile
make it an appealing treatment option.”
Anavex Life Sciences highlighted that dizziness was the most common adverse
event, occurring transiently and mostly mildly. This was reported in 35.8% of
participants during titration, compared to 6.0% in the placebo group.
Christopher U Missling, PhD, CEO of Anavex, expressed optimism about the findings. “These
results are a testament to our commitment to advancing Alzheimer’s disease
treatment. We are grateful to all study participants and look forward to
further developing blarcamesine as a potential oral treatment option.”
This study marks a significant step forward in Alzheimer’s research, offering new hope for
patients and caregivers battling this debilitating disease. Anavex Life
Sciences’ dedication to scientific advancement continues to drive progress in
the field. Refer to this article for related information.
Learn more about Anavex on https://www.marketwatch.com/investing/stock/avxl
